ClinicalTrials.govpublic full text
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
hormone-sensitive prostate cancer, prostate cancer, de novo metastatic prostate cancer, pten, pten deficiency, hormones, hormone-sensitive, androgen deprivation therapy, capivasertib, abiraterone, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 882298
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.